Figure 5 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma by Jessica D. Daley (22128489)

Oseltamivir treatment decreases the magnitude of the effector influenza-specific CD8⁺ T cell responses. by Nicola L. Bird (182542)

Decrease in fecundity with <i>PPR</i>. by Corinne Vacher (272363)

ALVAC-HIV elicits V2, V3, and CD4 inducible (CD4i) binding antibody responses. by LaTonya D. Williams (3140490)

Subjects:

ATRA decreases mRNA expression of HO-1, GCLM and x-CT and lowers GSH level in BTZ-treated cells. by A. L. Furfaro (2587792)

The NK1-receptor antagonist ezlopitant significantly decreases the breakpoint for sucrose but not ethanol operant self-administration in rats. by Pia Steensland (362091)

“…<p>Ezlopitant (5 and 10 mg/kg i.p.) decreases the breakpoint for 5% sucrose using a PR schedule (<b>A</b>), but had no effect on the breakpoint for 10% ethanol (<b>B</b>). …”

Dose-dependent increase in NREM sleep and decrease in wakefulness by <i>p</i>.<i>o</i>. administration of TEG in mice. by Mahesh K. Kaushik (3753871)

“…<p>(A, B) Typical examples of EEG delta power (0.5–4 Hz), EMG integral, and hypnograms of a mouse after <i>p</i>.…”

FXR decreases in mice livers with pathological injuries induced by <i>S</i>. <i>japonicum</i> infection. by Beibei Zhang (509356)

Validation of primary screen hits reveals compounds that recapitulate increased spheroid size (swell) or decreased MUC5AC in the lumen. by Pranjali Beri (14945400)

“…Compounds that appeared to cause toxicity were identified by observing a significant decrease in spheroid counts in the swell readout or a significant decrease in the total nuclear intensity of the MUC5AC ratio readout. …”

ATRA decreases the binding of Nrf2 to ARE sequences in the promoter regions of HO-1, GCLM and x-CT in BTZ-treated cells. by A. L. Furfaro (2587792)

Decrease in adhesion during early development of <i>Dictyostelium discoideum</i>. by Marco Tarantola (102609)

IGF-1 injections alone do not alter the immune phenotype at day 30. by Jordan A. Gunning (18143970)

Subjects:

Decreased NK1.1 during NKT cell development in <i>Hnrpll</i>^thu/thu mice. by Mehmet Yabas (340094)

EHD2 siRNA treated HUVEC showed decreased NO generation and cytosolic Ca²⁺ response. by Claudia Matthaeus (7485782)

Inhibition of VEGF-A gene synthesis decreased ranibizumab and aflibercept mediated CCL2 CCL5, and CX3CL1 mRNA and protein levels in HCAECs. by Clare Arnott (2557705)

Drp1^SD overexpression in <i>opa1</i> RNAi and <i>marf</i> RNAi expressing type II NB lineages suppresses the differentiation defect. by Dnyanesh Dubal (12085942)

AIM-100 reduces dsRNA silencing in body wall muscle and decreases DA neurodegeneration. by Anthony L. Gaeta (13272609)

Inhibitor treatment decreases capsule production in different pathogenic <i>E. coli</i> serotypes. by Carlos C. Goller (245570)

Binding of C4BP decreases the association of CEACAM-binding Opa+ <i>N</i>. <i>gonorrhoeae</i> with neutrophils. by Lacie M. Werner (14710419)

Decreased remyelination initiation is observed in Scribble cKO mice following focal demyelination in corpus callosum. by Andrew A. Jarjour (343100)

“…In the contralateral (unlesioned) hemisphere (CL), no difference was seen in the proportion of axons in the corpus callosum that were myelinated in Scribble cKO compared to wild-type animals (A–C). Fewer remyelinated axons were observed in corpus callosum in the lesion area in Scribble cKO mice (E) relative to controls (D) as quantified in F; 0.4–0.5 μm: WT = 80.0% ± 9.8%, cKO = 41.3% ± 8.9% myelinated; 0.5–0.6 μm: WT = 79.4% ± 6.3%, cKO = 41.5% ± 9.5% myelinated; 0.6–0.7 μm: WT = 91.6% ± 3.0%, cKO = 44.3% ± 8.7% myelinated; >0.7 μm: WT = 92.7% ± 1.9%, cKO = 47.9% ± 2.5% myelinated. …”